PharmacovigilanceOfficial
EMA publishes PSUSA outcome for cytomegalovirus immunoglobulin: marketing authorisations to be maintained
🇪🇺 EMA · Thu 19 Nov 2026
The EMA has published the outcome of a periodic safety update report single assessment for cytomegalovirus immunoglobulin, with the regulatory outcome recorded as maintenance.
The European Medicines Agency (EMA) published on 19 November 2026 the outcome of procedure PSUSA/00000914/202601, a periodic safety update report single assessment covering the active substance cytomegalovirus immunoglobulin.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (EMA). AI-assisted; check the source before acting.
More Pharmacovigilance
All →
FDA early alert: Heraeus Medevio recalls vascular guidewires over hydrophilic coating clumping risk
🇺🇸 FDA MedWatch · Fri 20 Nov 2026
EMA publishes PSUSA outcome for ibuprofen medicines, concluding with a variation
🇪🇺 EMA · Fri 20 Nov 2026
EMA publishes PSUSA outcome for nationally authorised split-virion inactivated influenza vaccines, recommending a variation
🇪🇺 EMA · Fri 20 Nov 2026
CMS proposes Medicare Advantage rule to ease market entry and widen beneficiary choice
🇺🇸 CMS · Fri 20 Nov 2026
CMS issues proposed rule on 2028 Medicare Advantage and Part D changes
🇺🇸 CMS · Fri 20 Nov 2026
FDA warns Florida clinical investigator over consent failings in INSTI HIV self-test study
🇺🇸 FDA CBER · Fri 20 Nov 2026